Table 2.
Second cancers in GH-treated patients included in the main analysis.
| Previous history of neoplastic disease | Second cancer observed during HypoCCS | Age at cancer onset (years)a | GHD onset type | Sex |
|---|---|---|---|---|
| Astrocytoma/oligoastrocytoma | Glioblastomab | 31.1 | AO | F |
| Astrocytoma | Thyroid cancer | 25.4 | CO | F |
| Astrocytoma | Uterine cancer | 53.7 | AO | F |
| Medulloblastoma | Glioblastoma | 20.2 | CO | M |
| Medulloblastoma | Papillary thyroid carcinoma | 34.9 | CO | M |
| Pineal dysgerminoma | Glioblastoma multiforme | 31.4 | CO | M |
| Acute lymphocytic leukemia | Malignant melanoma | 31.4 | CO | F |
| Lymphoblastic leukemia | Ewing sarcoma | 16.8 | CO | M |
| Basal cell carcinoma | Polycythemia vera | 65.9 | AO | M |
| Basal cell carcinoma and pituitary adenoma | Malignant melanoma | 84.0 | AO | M |
| Basal cell carcinoma and pituitary adenoma | Pancreatic islet cell cancer | 69.5 | AO | F |
| Basal cell carcinoma, skin cancer, and craniopharyngioma | Lentigo maligna | 81.9 | CO | M |
| Malignant melanoma | Malignant melanomab | 57.6 | AO | F |
| Squamous cell carcinoma and pituitary adenoma | Malignant melanoma | 64.7 | AO | M |
| Breast cancer and pituitary adenoma | Lung cancer | 73.1 | AO | F |
| Cervical cancer | Glioma | 61.3 | AO | F |
| Hemangiopericytoma | Lymphoma | 67.1 | AO | M |
| Lung cancer and pituitary adenoma | Colon adenocarcinoma | 77.3 | AO | M |
| Maxillary sinus cancer | Lung cancer | 60.4 | AO | F |
| Nasopharyngeal carcinoma | Malignant soft tissue tumor | 47.9 | AO | M |
| Papillary thyroid cancer, meningioma | Endometrial adenocarcinoma | 73.5 | AO | F |
AO, adult onset; CO, childhood onset; F, female; GHD, GH deficiency; M, male.
a
During HypoCCS participation.
b
Potentially recurrent cancers, but second malignancy could not be discounted.